AOD9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-07. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Lactobacillic acid, scientifically 10-(2-hexylcyclopropyl) decanoic acid, is a naturally occurring chemical compound from the group of fatty acids. Its salts are called lactobacillates. A special feature is the cyclopropane ring in the carbon chain. Lactobacillic acid, with 19 carbon atoms, is an odd-chain fatty acid. The fatty acid was detected in the 1950s in bacteria of the genus Lactobacillus, but is also found in numerous other bacterial species. The bacterial biosynthesis of lactobacillic acid takes place from cis-vaccenic acid (cis-11-octadecenoic acid), a unsaturated fatty acid that has one carbon atom less. Bacteria in a batch culture form the fatty acid at the end of the exponential phase of growth or in the early stationary growth phase. Previous studies have shown that the biosynthesis and storage of lactobacillic acid in the cell membrane is associated with a protective effect for the bacterial cells, although the exact mechanism has not been conclusively clarified. In bacteriology, the fatty acid is mainly used for analytical purposes, for example in the identification of bacteria.
Chloramphenicol is available as a capsule or as a liquid. In some countries, it is sold as chloramphenicol palmitate ester (CPE). CPE is inactive, and is hydrolysed to active chloramphenicol in the small intestine. No difference in bioavailability is noted between chloramphenicol and CPE. Manufacture of oral chloramphenicol in the U.S. stopped in 1991, because the vast majority of chloramphenicol-associated cases of aplastic anaemia are associated with the oral preparation. No oral formulation of chloramphenicol is available in the U.S. for human use.
college sports) SOD (i/a) School Of Dentistry Statement Of Difference(s) Statement Of Direction Statement Of Documentation Statement Of Duty/Duties SOE (i) Secret Of Evermore Special Operations Executive (WWII British organization) State Of Emissions (EW) SOF (a/i) Special Operations Force(s) Status of Forces SOFIA – (a) Stratospheric Observatory For Infrared Astronomy SOGAT (a) Society of Graphical and Allied Trades Former British printing union SOHC – (i) Single-OverHead-Cam engine SOHO – (p) Solar and Heliospheric Observatory SOI (i) Signal Operating Instruction (i) Southern Oscillation Index SOL – (i) Shit Out of Luck SOLIS – (i) Synoptic Optical Long-term Investigations of the Sun som – (s) Somali language (ISO 639-2 code) SOM (a) Simulation Object Model (s) Somalia (ISO 3166 trigram) Sonar – (p) SOund Navigation And Ranging SOP (i) Standing/Standard Operating Procedure State of Play SOR (i) State Of Readiness Statement Of Requirements SOS (s) Somali shilling (ISO 4217 currency code) Save Our Souls SOSTAR – (a) Stand-Off Surveillance and Target Acquisition Radar sot – (s) Sotho language (ISO 639-2 code) SOUTHAG – (p) Southern Army Group SOUTHCOM – (p) (U.S.) Southern Command SOV – (i) Single Occupant Vehicle SOW – (i) Statement Of Work SOWHAT – (p) RESNA Subcommittee on Wheelchairs and Transportation SOX – (p) Sarbanes–Oxley Act
Sources: en.wikipedia.org
Amino acid-based formula is a type of infant milk formula made from individual amino acids. It is hypoallergenic and intended for infants suffering from severe allergy to milk and various gastrointestinal conditions, such as food protein-induced enterocolitis syndrome and malabsorption syndromes. It is sometimes referred to as elemental formula but this is considered a misleading name. Issues with the use of amino acid-based formula include its high cost and its unpalatable taste. Intake of amino-acid formula for healthy infants shows no advantage in growth.
=== Metal speciation === A growing trend in the world of elemental analysis has revolved around the speciation, or determination of oxidation state of certain metals such as chromium and arsenic. The toxicity of those elements varies with the oxidation state, so new regulations from food authorities requires speciation of some elements. One of the primary techniques to achieve this is to separate the chemical species with high-performance liquid chromatography (HPLC) or field flow fractionation (FFF) and then measure the concentrations with ICP-MS.
A black neon tetra inadvertently caused their owner's credit card to be charged during a 2023 livestream by "Mutekimaru Channel" on YouTube. The owner was using motion-tracking software to turn the fish's movements into Nintendo Switch inputs, letting them "play" video games. In 2020, the fish beat Pokemon Sapphire after 3,195 hours, a feat that takes about 30 hours for a typical human. On January 14, 2023, Pokémon Violet crashed at 1,144 hours, giving the fish free access to the main menu. They entered inputs that opened Nintendo eShop, added 500 yen ($3.85 USD) to their owner's account, and exposed his credit card details on the livestream. Mutekimaru later requested a refund of the 500 yen from Nintendo. Several media outlets facetiously described the fish as having committed "credit card fraud". The fish also downloaded an N64 emulator, set up PayPal, used reward points to buy an avatar, and changed Mutekimaru's Nintendo account name to "ROWAWAWA¥". After about seven hours, their movements shut down the Switch.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.